Table 1 Baseline demographic and clinical characteristics in the concept elicitation interviews of Stage 1

Age (years), mean (SD)

64.2 (9.5)

Female, n (%)

12 (60.0)

Race, n (%)

 White/Caucasian

 Black African or Caribbean

10 (50.0)

10 (50.0)

Clinical characteristics

Time since COPD diagnosis (months), mean (SD)

45.1 (27.6)

Time since muscle weakness diagnosis (months), mean (SD)

22.9 (15.4)

Baseline predicted FEV₁(%), mean (SD)

50.1 (11.2)

Predicted FEV₁, n (%)

 20–29%

 30–39%

 40–49%

 50–59%

 60–69%

 70–80%

1 (5)

2 (10)

4 (20)

10 (50)

2 (10)

1 (5)

BMI (kg/m²), mean (SD)

26.6 (3.6)

COPD exacerbations since diagnosis, n (%)

 0

 1

 2

 3

6 (30.0)

9 (45.0)

3 (15.0)

2 (10.0)

Patients hospitalized in the past 12 months, n (%)

 0

 1

 2

15 (75.0)

3 (15.0)

2 (10.0)

CAT score, mean (SD)

20.3 (6.9)

Current treatments for COPD, n (%)

 ICS

 LABA

 LAMA

19 (95.0)

20 (100.0)

11 (55.0)

Severity of muscle weakness condition, n (%)

 Mild

 Moderate

 Severe

8 (40.0)

9 (45.0)

3 (15.0)